KSM Feed

Our new study on COVID-19 vaccine effectiveness in patients with Inflammatory Bowel Disease (IBD).

Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.

Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.

Most respondents are in favor of vaccinating 12-16 year olds – men more in favor than women.

New KSM research in association with IBM: Trends in clinical characteristics of severe non-respiratory events related to Coronavirus patients.

Our new survey on behaviour attitudes towards preventive measures following Coronavirus vaccination.

The rate of children diagnosed with celiac in Israel has increased almost threefold over a decade.

Continuing to monitor vaccinated members – 62 days following the first vaccine dose.

Our new study on Coronavirus reinfection.

KSM is publishing a new real world data study on reinfected Maccabi members.

A retrospective analysis of serological data in 116 Israeli healthcare workers administered with the Coronavirus vaccine.

Continuing to monitor vaccinated members. Coronavirus update February 18.

Continuing to monitor vaccinated members. Coronavirus update February 10.

Continuing to monitor vaccinated members at Maccabi.

New analysis 28 days after the first vaccination dose.